<table frame="void" id="A840AF15-7E64-4944-B567-4374C36F8EE3" xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 1:  Select Mean (±S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin</caption>
<tfoot>
<tr><td valign="top"><sup>a </sup>All doses given fasting except the first 18 doses of the multiple dose studies;</td></tr>
<tr><td valign="top"><sup>b</sup> Peak plasma concentration;</td></tr>
<tr><td valign="top"><sup>c</sup> Time to peak plasma concentration;</td></tr>
<tr><td valign="top"><sup>d</sup> Combined results (average means) of five studies: mean age 32 years (range 23-59 yrs).</td></tr>
<tr><td colspan="2" valign="top"><sup>e</sup> Kinetic study done following dose 19, given fasting</td></tr>
<tr><td colspan="5" valign="top"><sup>f</sup> Elderly subjects, mean age 71 years (range 65-81 years)</td></tr>
<tr><td colspan="5" valign="top"><sup>g</sup> CL<sub>cr</sub> = creatinine clearance normalized to body surface area of 1.73 m<sup>2</sup></td></tr>
</tfoot>
<tbody>
<tr><td align="left" valign="top"><content stylecode="bold">Subject Groups: </content>Metformin<content stylecode="bold">dose</content><content stylecode="bold"><sup>a</sup></content><content stylecode="bold"> (number of subjects)</content></td><td align="center" valign="top"><content stylecode="bold">C</content><content stylecode="bold"><sub>max </sub></content><content stylecode="bold"><sup>b</sup></content><content stylecode="bold">(μg/mL)</content></td><td align="center" valign="top"><content stylecode="bold">T</content><content stylecode="bold"><sub>max </sub></content><content stylecode="bold"><sup>c</sup></content><content stylecode="bold">(hrs)</content></td><td align="center" valign="top"><content stylecode="bold">Renal Clearance</content><content stylecode="bold">(mL/min)</content></td></tr>
<tr><td align="left" valign="top"><content stylecode="bold">Healthy, nondiabetic adults:</content>500 mg single dose<sup></sup>(24)850 mg single dose (74)<sup>d</sup>850 mg three times daily for 19 doses<sup>e</sup> (9)</td><td align="left" valign="top">1.03 (±0.33)1.60 (±0.38)2.01 (±0.42)</td><td align="left" valign="top">2.75 (±0.81)2.64 (±0.82)1.79 (±0.94)</td><td align="left" valign="top">600 (±132)552 (±139)642 (±173)</td></tr>
<tr><td align="left" valign="top"><content stylecode="bold">Adults with type 2 diabetes:</content>850 mg single dose (23)850 mg three times daily for 19 doses<sup>e </sup>(9)</td><td valign="top">1.48 (±0.5)1.90 (±0.62)</td><td valign="top">3.32 (±1.08)2.01 (±1.22)</td><td align="center" valign="top">491 (±138)550 (±160)</td></tr>
<tr><td align="left" valign="top"><content stylecode="bold">Elderly</content><sup>f</sup><content stylecode="bold">, healthy nondiabetic adults:</content>850 mg single dose (12)</td><td align="center" valign="top">2.45 (±0.70)</td><td align="center" valign="top">2.71 (±1.05)</td><td align="center" valign="top">412 (±98)</td></tr>
<tr><td align="left" valign="top">Renal-impaired adults: 850 mg single dose<content stylecode="bold">Mild </content>(CL<sub>cr </sub><sup>g</sup> 61-90 mL/min) (5)<content stylecode="bold">Moderate</content> (CL<sub>cr</sub> 31-60 mL/min) (4)<content stylecode="bold">Severe</content> (CL<sub>cr</sub> 10-30 mL/min) (6)</td><td align="center" valign="top">1.86 (±0.52)4.12 (±1.83)3.93 (±0.92)</td><td align="center" valign="top">3.20 (±0.45)3.75 (±0.50)4.01 (±1.10)</td><td align="center" valign="top">384 (±122)108 (±57)130 (±90)</td></tr>
</tbody>
</table>